Immunotherapy and Targeted Therapy Flashcards
6 cards from real Mesothelioma Therapy practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 Immunotherapy and Targeted Therapy flashcards as text
Which immune checkpoint combination showed a statistically significant overall survival benefit in CheckMate 743 for mesothelioma?
Answer: Nivolumab + ipilimumab vs. chemotherapy
CheckMate 743 demonstrated a statistically significant overall survival benefit for nivolumab + ipilimumab versus standard chemotherapy in unresectable pleural mesothelioma.
Tumor Treating Fields (TTFields) therapy is approved in the US for mesothelioma in combination with which treatment?
Answer: Pemetrexed + platinum chemotherapy
TTFields (NovoTTF-100L) received FDA approval in combination with pemetrexed + platinum chemotherapy for unresectable pleural mesothelioma.
What is the mechanism of Tumor Treating Fields (TTFields) therapy?
Answer: Creating alternating electric fields that disrupt cancer cell division
TTFields uses low-intensity, alternating electric fields to disrupt microtubule formation during cell division, selectively killing rapidly dividing cancer cells.
Which serum biomarker may be used to monitor response to immunotherapy in mesothelioma?
Answer: Soluble mesothelin-related peptides (SMRP)
Soluble mesothelin-related peptides (SMRP) is a serum biomarker that may be useful in monitoring treatment response in mesothelioma patients.
Which genetic pathway alteration is under investigation as a target in sarcomatoid mesothelioma?
Answer: SWI/SNF chromatin remodeling complex (SMARCA4/ARID1A)
Mutations in the SWI/SNF chromatin remodeling complex, including SMARCA4 and ARID1A, are being investigated as therapeutic targets in sarcomatoid mesothelioma.
What is the primary reason immunotherapy shows greater benefit in non-epithelioid mesothelioma compared to chemotherapy?
Answer: Non-epithelioid cells are resistant to chemotherapy, making immunotherapy relatively more effective
Non-epithelioid mesothelioma is inherently chemotherapy-resistant, making the survival advantage of immunotherapy more pronounced relative to standard chemotherapy.